Novartis (NYSE:NVS) Gains on Q2 Beat; Boosts Outlook
Market News

Novartis (NYSE:NVS) Gains on Q2 Beat; Boosts Outlook

Shares of healthcare major Novartis AG (NYSE:NVS) are up nearly 4% at the time of writing today after the company posted better-than-anticipated second-quarter numbers while also boosting its outlook.

Revenue rose 6.6% year-over-year to $13.62 billion, outperforming estimates by $410 million. EPS at $1.83 too landed past expectations by $0.07.  During the quarter, Entresto, Kesimpta, Pluvicto, and Kisquali continued to perform well with sales in the Innovative Medicines segment rising ~9% and Sandoz segment sales rising ~5%. Further, the growth in the top line, coupled with lower restructuring charges, helped Novartis boost its operating income by nearly 50% during this period.

What’s more, the company has also initiated a share repurchase program of nearly $15 billion. The stock buyback is expected to be completed by the end of 2025. Novartis Board has also given its blessing to the planned 100% spin-off of Sandoz. The strategic move is expected to be completed by the fourth quarter.

Buoyed by the robust business momentum, Novartis now expects full-year 2023 sales to rise by a high single-digit versus an earlier expectation of mid-single-digit growth. Core operating income for the year is seen growing in the low double digits as compared to the prior outlook of high single-digit growth.

Overall, the Street has a $118.50 consensus price target on Novartis alongside a Moderate Buy consensus rating.  Shares of the company have gained nearly 19.6% over the past year.

Read full Disclosure

Related Articles
TheFlySchrodinger announces expanded license agreement with Novartis
TheFlyMediciNova notified of settlement in Sanofi Novartis litigation
TheFlyNovartis price target lowered to CHF 100 from CHF 105 at Deutsche Bank
Go Ad-Free with Our App